Obesity Prompts Vivus Takeover Talk With 88% Windfall: Real M&A

Vivus Inc.’s shareholders are poised to reap an 88 percent windfall in a takeover after the company’s weight-loss drug moved one step closer to winning approval to treat America’s 78 million obese adults.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.